1. Academic Validation
  2. Tau Derived Hexapeptide AcPHF6 Promotes Beta-Amyloid (Aβ) Fibrillogenesis

Tau Derived Hexapeptide AcPHF6 Promotes Beta-Amyloid (Aβ) Fibrillogenesis

  • ACS Chem Neurosci. 2018 Apr 18;9(4):773-782. doi: 10.1021/acschemneuro.7b00433.
Tarek Mohamed 1 Sarbjeet Singh Gujral 1 Praveen P N Rao 1
Affiliations

Affiliation

  • 1 School of Pharmacy, Health Sciences Campus , University of Waterloo , 200 University Avenue West , Waterloo , Ontario , Canada N2L 3G1.
Abstract

We studied the interactions of a tau derived hexapeptide AcPHF6 with β-Amyloid Peptides Aβ40 and Aβ42 which reveals its unusual ability to promote Aβ fibrillogenesis. The results demonstrate that the N-acetylated and C-amidated AcPHF6 hexapeptide can cause significant acceleration in Aβ40 and Aβ42 fibril growth. Aggregation kinetic studies at pH 7.4 show that at 25 μM, AcPHF6 hexapeptide was able to cause ∼2.3-fold increase in Aβ40 fibrillogenesis dramatically changing the aggregation kinetics. In addition, AcPHF6 peptide was able to reduce cellular toxicity mediated by Aβ40 and Aβ42 in hippocampal neuronal cell line (HT22). Computational studies suggest that the AcPHF6 peptide can act as an anchor and provides a hydrophobic surface for Aβ monomer to bind and undergo rapid fibrillogenesis to form less toxic fibrils and alter the aggregation kinetics. At the molecular level we propose a "dock-and-pack" mechanism where the AcPHF6 hexapeptide aggregates can stabilize the β-hairpin and promote rapid Aβ self-assembly and growth to form less toxic oligomers or fibrils. Our results have direct implications in designing novel peptide/peptidomimetics as novel pharmacological tools to study protein aggregation and potentially prevent Aβ-mediated toxicity in Alzheimer's disease.

Keywords

Alzheimer’s disease; aggregation kinetics; beta-amyloid; hexapeptide; molecular docking; neuroprotection; transmission electron microscopy.

Figures
Products